CD274 and neoplasm: Atezolizumab showed in post‐chemotherapy metastatic cancer good efficacy, which was associated with tumour infiltration immune cell (TIC) PD‐L1 expression (p = 0.026) but not tumour cell PD‐L1 expression (p = 0.93) and favourable toxicity profile.